Next 10 |
home / stock / mrna / mrna articles
The European Commission faced criticism from Europe’s second-highest court regarding transparency issues surrounding COVID-19 vaccine contrac...
The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell sh...
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping ...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 37.68% on an annualized basis producing an average annual return of 50.8...
Moderna, Inc. (NASDAQ:MRNA) shares are trending on Wednesday. The company received a $176 million award from the Rapid Response Partnership Vehicle...
Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High C...
In response to the growing threat of the H5N1 bird flu virus, the U.S. government has awarded a $176 million contract to Moderna Inc. (NASDAQ:MRNA)...
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio? Walgreens Boots Alliance, Inc. (NASDAQ:WBA) sh...
Moderna, Inc. (NASDAQ:MRNA) stock is trending on Friday. The company announced that the European Medicines Agency’s Committee for Medicinal P...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...